Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes  by Mallat, Ziad et al.
C
A
P
Z
M
O
A
G
A
P
P
i
f
a
(
s
t
s
(
I
U
C
0
P
*
H
F
K
S
o
p
R
S
a
Journal of the American College of Cardiology Vol. 46, No. 7, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PAcute Coronary Syndromes
irculating Secretory Phospholipase A2
ctivity Predicts Recurrent Events in
atients With Severe Acute Coronary Syndromes
iad Mallat, MD, PHD,* Ph. Gabriel Steg, MD, PHD,† Joëlle Benessiano, MD, PHD,‡
arie-Laure Tanguy, PHD,§ Keith A. Fox, FESC, Jean-Philippe Collet, MD, PHD,¶
mar H. Dabbous, MD, MPH,# Patrick Henry, MD,** Kathryn F. Carruthers, MPHIL,
nne Dauphin, MSC,‡ Carla Sibella Arguelles, MSC‡ Joëlle Masliah, PHD,†† Bénédicte Hugel, PHD,‡‡
illes Montalescot, MD, PHD,¶ Jean-Marie Freyssinet, PHD,‡‡ Bernard Asselain, PHD,§
lain Tedgui, PHD*
aris, Strasbourg, and Le Kremlin-Bicêtre, France; Edinburgh, United Kingdom; and Worcester, Massachusetts
OBJECTIVES The purpose of this study was to determine the prognostic value of circulating secretory
phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS).
BACKGROUND The plasma level of type IIA sPLA2 is a risk factor for coronary artery disease (CAD) and
is associated with adverse outcomes in patients with stable CAD. The prognostic impact of
sPLA2 in patients with ACS is unknown.
METHODS Secretory phospholipase A2 antigen levels and activity were measured in plasma samples of
446 patients with ACS, obtained at the time of enrollment.
RESULTS Baseline sPLA2 activity was associated with the risk of death and myocardial infarction (MI).
The unadjusted rate of death and MI increased in a stepwise fashion with increasing tertiles
of sPLA2 activity (p  0.0001). The association remained significant in the subgroup of
patients who had MI with ST-segment elevation (p  0.014) and the subgroup of patients
who had unstable angina or non–ST-segment elevation MI (p 0.002). After adjustment for
clinical and biological variables, the hazard ratios for the combined end point of death or MI
in the third tertile of sPLA2 compared with the first and second tertiles was 3.08 (95%
confidence interval, 1.37 to 6.91, p  0.006).
CONCLUSIONS A single measurement of plasma sPLA2 activity at the time of enrollment provides strong
independent information to predict recurrent events in patients with ACS. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.056Cardiol 2005;46:1249–57) © 2005 by the American College of Cardiology Foundation
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ihospholipase A2 (PLA2) enzymes hydrolyze phospholip-
ds at the sn-2 position to generate lysophospholipids and
atty acids (1). One of the most extensively studied PLA2 is
low-molecular-weight (14 kDa) group IIa secretory PLA2
sPLA2), expressed in normal human arteries and athero-
clerotic plaques (2), and associated with enhanced suscep-
ibility to atherogenesis in animals (3). The plasma level of
PLA2 is elevated in patients with coronary artery disease
CAD) and predicts coronary events in stable patients (4).
ncreased plasma level of sPLA2 in stable patients under-
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teg contributed equally to this work.c
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ccepted June 6, 2005.oing percutaneous coronary angioplasty also provides in-
ependent prognostic information over other classic biolog-
cal and clinical variables (5). Studies evaluating the
rognostic value of sPLA2 in patients with acute coronary
yndromes (ACS) are limited to a small study of patients
ith unstable angina (UA), where increased plasma levels of
PLA2 predicted recurrent coronary events, mainly revas-
ularization procedures, independently of other risk factors
6). Noteworthy, sPLA2 activity has not been directly
etermined in the previously published studies, and no
nformation is available on the prognostic implications of
PLA2 activity in patients with ACS. These include pa-
ients with ST-segment elevation myocardial infarction
STEMI), patients with myocardial infarction (MI) but no
T-segment elevation (NSTEMI), and patients with UA.
e sought to evaluate the prognostic implications of plasma
PLA2 activity across the entire spectrum of ACS by
ecruiting patients from the Global Registry of Acute
oronary Events (GRACE). In parallel, we measured
lasma levels of two other systemic inflammatory markers,
he classic high-sensitivity C-reactive protein (CRP), and
nterleukin (IL)-18, a potent pro-atherogenic cytokine re-
ently shown to provide strong independent prognostic
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sPLA2 Activity and Major Coronary Events October 4, 2005:1249–57nformation in patients with coronary heart disease but
hose prognostic value in patients with ACS has not been
valuated.
ETHODS
tudy sample. Full details of the GRACE methodology
ave been published (7–9). Patients included in this sub-
tudy (from September 28, 2000, to October 24, 2002) were
ecruited in three centers in France and one center in
cotland. The study was approved by institutional review
ommittees and the subjects gave informed consent. Inclu-
ion criteria for the present study were age 18 years, a
resumptive diagnosis of ACS, and at least one of the
ollowing criteria: dynamic electrocardiographic (ECG)
hanges consistent with ACS, serial increases in serum
iochemical markers of cardiac necrosis, and/or documen-
ation of CAD. Exclusion criteria were recent MI with
ersistent elevation of serum biochemical markers of cardiac
ecrosis, Killip class IV, trauma, surgery, significant co-
orbidity, life expectancy of less than six months, a diag-
osis of cancer, human immunodeficiency virus positivity,
octurnal paroxysmal hemoglobinuria, hemolytic uremic
yndrome, thrombotic thrombocytopenic purpura, auto-
mmune thrombocytopenia, heparin-induced thrombocyto-
enia, anti-phospholipid syndrome, systemic lupus ery-
hematosus, and Crohn’s disease. Patients were followed up
y telephone, clinic visits, or calls to the primary care
hysician. Standardized definitions of all patient-related
ariables and clinical diagnoses were used as well as hospital
omplications and outcomes. All cases were assigned to one
f the following categories: STEMI, NSTEMI, or UA.
hese definitions take into account clinical presentation,
CG findings, and the results of serum biochemical mark-
rs of necrosis. Unstable angina was defined as ACS with
ormal biochemical markers of necrosis (particularly tropo-
in I).
lood sampling and biochemical analyses. Blood samples
ere collected in heparin tubes at the time of enrollment
the first working morning following admission) and imme-
iately centrifuged at 3,000 rpm at 4°C for 10 min. The
esulting plasma was aliquoted, frozen, and shipped on dry
Abbreviations and Acronyms
ACS  acute coronary syndromes
CAD  coronary artery disease
CRP  C-reactive protein
GRACE  Global Registry of Acute Coronary Events
hsCRP  high-sensitivity CRP
IL  interleukin
MI  myocardial infarction
NSTEMI  non–ST-segment elevation MI
STEMI  ST-segment elevation MI
sPLA2  secretory type II phospholipase A2
UA  unstable anginace to Hôpital Bichat-Claude Bernard (Paris, France), where
p
Shey were maintained at 70°C until analyzed. C-reactive
rotein was measured by a high-sensitivity test, performed
n a Behring BN II analyzer (Behring Diagnostics, Deer-
eld, Illinois), and cardiac troponin I was quantified with an
utomated system (RXL HM analyzer, Dade Behring).
igh-sensitivity IL-18 was measured with a human ELISA
it (MBL Co., Nagoya, Japan) with a detection limit of 12.5
g/ml. Levels of immunoreactive sPLA2 in plasma were
easured by an immunometric assay on the basis of a
ouble-antibody “sandwich” technique, with a monoclonal
ntibody specific for sPLA2 (Cayman Chemical Company,
nn Arbor, Michigan). This antibody has no cross-
eactivity with type I, IV, or type V sPLA2 (Cayman
hemical Company). Cross-reactivity with type X sPLA2
as not been tested. The minimum detectable concentration
as 15.6 pg/ml. and the intra and interassay coefficient of
ariation (CV) was 10%. Plasma sPLA2 activity was
easured by a selective fluorimetric assay of Radvanyi et al.
10), as modified by Pernas et al. (11). The sPLA2 activity
as measured with fluorescent substrate 1-hexadecanoyl-2-
1-pyredecanoyl)-sn-glycero-3 phosphomethanol, sodium
alt (Interchim, Montluçon, France). Of the fluorescent
ubstrate, 100% hydrolysis was measured with 0.1 U PLA2
rom bee venom (Sigma Chemical Co., Lyon, France). The
ydrolysis of substrate in the absence of plasma was used as
egative control and deduced from PLA2 activity. All
amples were tested in duplicate and plasma activity was
xpressed as nmol/min/ml. The minimum detectable activ-
able 1. Sample Characteristics
rench recruitment center (%) 63
ale (%) 76.6
ge, yrs (mean  SD) 61.1  13
edical history (%)
Infarction 22.9
Congestive heart failure 5.6
Coronary artery disease 28.5
Cerebrovascular disease 5.6
Diabetes 16.6
Hypertension 40.2
Hyperlipidemia 49.6
PCI 16.4
CABG 6.9
urrent or former smoker (%) 72.9
ndex diagnosis (%)
STEMI 38.5
NSTEMI 52.5
Unstable angina 9.0
illip class 1 (%) 20.5
roponin I, ng/ml (median–interquartile range) 2.55–17.3
RP, mg/l (median–interquartile range) 8.45–15.7
L18, pg/ml (median–interquartile range) 195–120
holesterol, mg/dl (median–interquartile range) 197.4–70.4
reatinine, mg/dl (median–interquartile range) 1.1–0.26
PLA2 activity, nmol/min/ml (median–interquartile range) 2.3–1.78
PLA2 antigen, ng/dl (median–interquartile range) 279–459
ABG  coronary artery bypass graft surgery; CRP  C-reative protein; IL 
nterleukin; NSTEMI  non–ST-segment elevation myocardial infarction; PCI 
ercutaneous coronary intervention; sPLA2  secretory type II phospholipase A2;
TEMI  ST-segment elevation myocardial infarction.
i
w
S
d
t
T
8
b
w
p
a
m
t
c
t
t
i
v
r
u
e
m
w
K
s
f
b
i
d
e
e
t
T
B
R
G
A
M
S
I
K
T
No 2.90 (2.0)
T
V
b
s
m
1251JACC Vol. 46, No. 7, 2005 Mallat et al.
October 4, 2005:1249–57 sPLA2 Activity and Major Coronary Eventsty was 0.10 nmol/min/ml and the intra- and interassay CV
as 10%.
tatistical analysis. Power calculations were conducted to
etect an adjusted hazard ratio of 3. This estimation was on
he basis of the results of the study by Kugiyama et al. (4).
he number of events planned to provide the study with
0% power with a risk alpha equal to 5% was calculated to
e 42. Assuming a six-month cumulative incidence of 10%,
ith unbalanced group sizes (one-third, two-third), 435
atients should be included.
We first studied relationships between plasma sPLA2
ctivity and clinical parameters: for binary variables, the
eans of sPLA2 levels were compared with the Student t
est. For index diagnosis, means of sPLA2 activity were
ompared with an analysis of variance. Relationships be-
ween sPLA2 activity and continuous parameters were
ested with Spearman’s rank correlation. To identify clinical
ndependent predictors of sPLA2 levels, variables with a p
alue 0.05 in univariate analysis were studied in multiva-
iable analysis by performing an analysis of covariance. We
sed a forward selection with a significance level of 0.05 for
ntering an explanatory variable into the multivariable
odel.
The predictive factors of death or MI were determined
ith survival analysis. Survival curves were derived from
aplan–Meier estimates. In univariate analysis, compari-
ons of the survival distributions were made by log-rank test
or clinical parameters and by univariate Cox regression for
iological markers (CRP, Troponin I, IL-18, sPLA2 activ-
ty, and sPLA2 antigen). These markers were a priori
ivided into tertiles and coded to two dummy variables. For
ach factor, hazards ratios and their confidence limits were
stimated with a univariate Cox model. Univariate predic-
able 2. Continued
Mean (SD)
of sPLA2
Activity
Univariate
p Value
Multivariable
p Value
Unfractionated heparin
Yes 2.93 (2.0) 0.0008 0.03
No 2.35 (1.2)
GP IIb/IIIa
Yes 2.71 (1.9) 0.6
No 2.60 (1.6)
Statin
Yes 2.53 (1.6) 0.09
No 2.84 (1.9)
ACE inhibitor
Yes 2.79 (1.9) 0.3
No 2.59 (1.6)
Beta blocker
Yes 2.62 (1.8) 0.5
No 2.77 (1.5)
ariables with a p 0.05 in univariate analysis were studied in multivariable analysis
y performing an analysis of covariance (see Methods). *Correlation coefficient with
PLA2: 0.2.
ACE  angiotensin-converting enzyme; GP  glycoprotein; LMW  low
olecular weight; other abbreviations as in Table 1.able 2. Association Between Plasma sPLA2 Activity and
aseline Clinical Variables
Mean (SD)
of sPLA2
Activity
Univariate
p Value
Multivariable
p Value
ecruitment center
Scotland 3.07 (1.9) 0.0001 0.0006
France 2.36 (1.5)
ender
M 2.59 (1.6) 0.4
F 2.77 (1.9)
ge * 0.0001 0.002
edical history
Infarction
Yes 2.48 (1.4) 0.3
No 2.67 (1.8)
Coronary artery disease
Yes 2.47 (1.4) 0.15
No 2.7 (1.8)
Cerebrovascular disease
Yes 2.79 (1.3) 0.6
No 2.63 (1.7)
Diabetes
Yes 3.03 (2.2) 0.08
No 2.55 (1.6)
Hypertension
Yes 2.81 (1.8) 0.07
No 2.51 (1.6)
Hyperlipidemia
Yes 2.36 (1.3) 0.001 0.04
No 2.88 (1.9)
PCI
Yes 2.33 (1.4) 0.06
No 2.69 (1.7)
CABG
Yes 2.33 (1.3) 0.3
No 2.65 (1.7)
moking status
Current or former
smoker
2.58 (1.7) 0.3
Never smoked 2.77 (1.8)
ndex diagnosis
Myocardial infarction
with ST-segment
elevation
2.99 (2.2)
Myocardial infarction
without ST-segment
elevation
2.42 (1.3) 0.002 0.01
Unstable angina 2.31 (1.4)
illip class
1 2.43 (1.5)
2 3.46 (2.2) 0.0001 0.04
3 3.24 (1.8)
reatment within first
24 hr hospital or
chronic use
Aspirin
Yes 2.65 (1.7) 0.2
No 2.29 (1.2)
Ticlopidine/clopidogrel
Yes 2.54 (1.7) 0.3
No 2.70 (1.7)
LMW heparin
Yes 2.36 (1.4) 0.001ors with a p value 0.05, were included in a stepwise
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sPLA2 Activity and Major Coronary Events October 4, 2005:1249–57Table 3. Univariate Survival Analysis
Cumulative Incidence of
Death/MI (SEM)*
Hazard Ratio
(95% Confidence Interval) p Value
Recruitment center
Scotland 10.5% (0.02) 1.81 (0.93–3.53) 0.08
France 6.0% (0.01)
Gender
F 7.9% (0.03) 1.13 (0.53–2.41) 0.7
M 7.7% (0.01)
Age
60 yrs 13.2% (0.02) 5.4 (2.26–13) 0.0001
60 yrs 2.3% (0.01)
Medical history
Infarction
Yes 14.9% (0.04) 3.2 (1.65–6.13) 0.0002
No 5.6% (0.01)
Congestive heart failure
Yes 27.9% (0.09) 4.41 (1.93–10.1) 0.0001
No 6.5% (0.01)
Coronary artery disease
Yes 12.1% (0.03) 2.27 (1.18–4.36) 0.01
No 6.1% (0.01)
Cerebrovascular disease
Yes 16.0% (0.07) 2.06 (0.73–5.83) 0.16
No 7.2% (0.01)
Diabetes
Yes 12.5% (0.04) 1.95 (0.94–4.05) 0.07
No 6.8% (0.01)
Hypertension
Yes 10.2% (0.02) 1.90 (1.01–3.55) 0.05
No 6.1% (0.01)
Hyperlipidemia
Yes 8.8% (0.02) 1.44 (0.74–2.8) 0.28
No 6.8% (0.02)
PCI
Yes 4.4% (0.02) 1.6 (0.57–4.52) 0.37
No 8.4% (0.01)
CABG
Yes 18.2% (0.07) 2.67 (1.11–6.41) 0.02
No 6.9% (0.01)
Smoking status
Never smoked 10.6% (0.03) 1.67 (0.86–3.27) 0.13
Current or former smoker 6.6% (0.01)
Index diagnosis
MI with ST-segment elevation 9.9% (0.02) 1.93 (0.96–3.86) 0.06
Other 5.7% (0.02)
Killip class
1 21.4% (0.04) 5 (2.62–9.7) 0.0001
1 4.3% (0.01)
Creatinine
1.1 14% (0.02) 6.2 (2.39–15.95) 0.0001
1.1 2% (0.01)
Total cholesterol
197 8.4% (0.02) 1.34 (0.59–3.06) 0.5
197 5.2% (0.02)
Treatment
LMW heparin
No 8.7% (0.02) 1.12 (0.57–2.2)
Yes 6.8% (0.02) 0.7
Unfractionated heparin
No 8.4% (0.02) 1.27 (0.64–2.52)
Yes 6.8% (0.02) 0.5
Revascularization (in hospital)
No 10.5% (0.02) 2.42 (1.16–5.05) 0.01
Yes 4.3% (0.01)Continued on next page
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October 4, 2005:1249–57 sPLA2 Activity and Major Coronary Eventsultivariable Cox regression model. The selection method
as a forward selection with a significance level of 0.05 for
ntering an explanatory variable into the model. The final
odel only includes significant variables with a p value
0.05 with the Wald test. Analyses were performed with
he SAS software package V8.2 (SAS Institute, Cary, North
arolina).
ESULTS
he study sample consisted of 446 patients with ACS,
8.5% with STEMI, 52.5% with NSTEMI, and 9% with
A. The median follow-up after admission was 6.5 months
25th percentile: 6 months; 75th percentile: 7.5 months).
he rate of in-hospital revascularization (percutaneous cor-
nary intervention or coronary artery bypass graft) was high:
8.3%. One year cumulative incidence of death or MI was
.63% (SEM: 0.02). Plasma sPLA2 activity ranged from
0.1 to 16.9 nmol/min/ml with a mean of 2.63  1.69
mol/min/ml. The time interval from onset of clinical
ymptoms to blood sampling was not associated with
lasma levels of sPLA2 activity (p  0.45).
ssociation of plasma sPLA2 activity with baseline clin-
cal and biological variables. Sample characteristics are
hown in Table 1 and clinical variables associated with
PLA2 activity are shown in Table 2. In multivariable
nalyses, significant predictors of high sPLA2 activity were
ecruitment center, age, diagnosis of STEMI at admission,
resentation with Killip class 1, and treatment by unfrac-
ionated heparin (Table 2). A history of hyperlipidemia was
ignificantly associated with lower sPLA2 activity (Table 2).
lasma sPLA2 activity showed moderate association with
RP (r  0.35, p  0.0001). Although statistically signif-
Table 3. Continued
Cumulative Incidence of
Death/MI (SEM)*
Troponin I
Tertile 1 6.2% (0.02)
Tertile 2 7.8% (0.02)
Tertile 3 9.4% (0.02)
CRP
Tertile 1 7.7% (0.02)
Tertile 2 7% (0.02)
Tertile 3 8.8% (0.02)
IL-18
Tertile 1 7.3% (0.02)
Tertile 2 7% (0.02)
Tertile 3 9.8% (0.02)
PLA2 antigen
Tertile 1 7.8% (0.02)
Tertile 2 5% (0.02)
Tertile 3 11.3% (0.03)
sPLA2 activity
Tertile 1 3% (0.01)
Tertile 2 5.1% (0.02)
Tertile 3 14.4% (0.03)
*Six months cumulative incidence of death/MI (SEM).
MI  myocardial infarction; HR  hazard ratio; other acant, the associations between sPLA2 activity and troponin p(r  0.23, p  0.0001), total cholesterol (r  0.24, p 
.0001), and low-density lipoprotein (LDL) cholesterol
r  0.24, p  0.0003) were weak. There was no
ssociation between sPLA2 activity and IL-18 levels (r 
.03, p  0.53). Secretory PLA2 activity showed moderate
ssociation with sPLA2 antigen levels (r  0.37, p 
.0001). This was not unexpected, because sPLA2 activity is
hat of the various sPLA2 subtypes, whereas sPLA2 antigen
evels only reflect the levels of the type IIA sPLA2.
ssociation of baseline plasma sPLA2 activity with clin-
cal outcomes. There were 35 major adverse events (20
eaths and 15 MI). No significant association was seen
etween clinical outcomes and either CRP or IL-18 levels
Table 3). The rate of death and new or recurrent MI
ncreased according to increasing tertiles of sPLA2 activity.
atients in the highest tertile of sPLA2 activity had a hazard
atio of 4.30 (95% confidence interval [CI], 2.1 to 8.7) for
eath or MI (p  0.0001) (compared with the other two
ertiles) (Fig. 1, Table 3). Adjustment for potential con-
ounders in a stepwise Cox regression model, including age,
history of hypertension, MI, heart failure, CAD, coronary
rtery bypass surgery, Killip class1, and creatinine level
1.1 did not alter the strong association between high
aseline levels of sPLA2 activity and increased risk of major
oronary events at follow-up (Table 3). The adjusted hazard
atio for the combined end point of death or MI in the third
ertile of sPLA2 activity, compared with the first and second
ertiles, was 3.08 (95% CI, 1.37 to 6.91) (p  0.006) (Table
). No significant association was found between sPLA2
ntigen level and the composite end point of death or MI
adjusted hazard ratio, 1.44, p  0.3). Finally, we verified
hat the GRACE score, previously shown to be highly
Hazard Ratio
(95% Confidence Interval) p Value
HR2,3 vs. 1:1.39 (0.59–3.30) 0.5
HR3 vs. 1,2:1.22 (0.57–2.61) 0.6
HR2,3 vs. 1:0.99 (0.43–2.3) 0.9
HR3 vs. 1,2:1.28 (0.58–2.81) 0.5
HR2,3 vs. 1:0.99 (0.43–2.28) 0.9
HR3 vs. 1,2:1.31 (0.6–2.89) 0.5
HR2,3 vs. 1:1 (0.51–2) 0.9
HR3 vs. 1,2:1.9 (0.96–3.6) 0.06
HR2,3 vs. 1:1.8 (0.5–6.2) 0.3
HR3 vs. 1,2:4.3 (2.1–8.7) 0.0001
ations as in Tables 1 and 2.redictive of event recurrence (12), significantly predicted
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sPLA2 Activity and Major Coronary Events October 4, 2005:1249–57dverse outcomes (MI/death) in the present study (hazard
atio for each 1-point increase in score, 1.03; 95% CI, 1.02
o 1.04, p  0.0001). Interestingly, sPLA2 activity re-
ained an independent predictor for recurrent events after
djusting for the GRACE score for recurrent events in a
ox regression model. The adjusted hazard ratio for the
ombined end point of death or MI in the third tertile of
PLA2 activity was 2.78 (95% CI, 1.30 to 5.93) (p 
.006).
ISCUSSION
nflammatory and thrombotic processes are major determi-
ants of atherosclerotic plaque complications leading to
CS and sudden death. The last decade has witnessed an
ncreasing interest in the study of the role of systemic
nflammatory markers and their relation to the severe
linical complications of atherosclerosis (13). Several circu-
ating inflammatory markers, including CRP, IL-6, vascular
ell adhesion molecule (VCAM)-1, and, more recently,
yeloperoxidase (14), have been shown to be elevated in
atients with ACS and to be associated with adverse clinical
utcomes (MI/death) at follow-up. In this study, we show
hat plasma sPLA2 activity, in contrast to CRP or IL-18, is
major independent predictor of death and new or recur-
ent MI in patients with ACS. In addition, whole sPLA2
ctivity has a better prognostic value than sPLA2 type IIA
ntigen level. Since the landmark study by Liuzzo et al. (15),
umerous studies have addressed the prognostic value of
RP in patients with ACS. Higher CRP levels were
igure 1. Kaplan-Meier curves showing the cumulative incidence of dea
hospholipase A2 (PLA2) activity.ssociated with increased risk at follow-up of patients with
TA or NSTEMI in several randomized trials, including
hrombolysis In Myocardial Infarction Phase IIA (TIMI
IA) (16), c7E3 Antiplatelet Therapy in Unstable Refrac-
ory Angina (CAPTURE) (17), Fragmin during Instability
n Coronary Artery Disease (FRISC) (18), and Global Use
f Strategies to Open Occluded Coronary Arteries
GUSTO-IV) (19). C-reactive protein levels in ACS pa-
ients assigned to early invasive revascularization procedures
lso predicted adverse outcomes (20); however, the inde-
endent predictive value of CRP for major adverse cardiac
vents in patients with STEMI or patients with ACS,
ecruited outside randomized clinical trials or treated with
arly revascularization, remains uncertain (21–23). In the
resent observational substudy from GRACE, CRP mea-
ured after admission for ACS (mostly STEMI and
STEMI) was not associated with adverse outcomes (MI/
eath). It should be noted, however, that the present study
myocardial infarction (MI) according to the tertile of secretory type II
able 4. Multivariable Analysis of the Predictors of Death
r MI
Death or MI HR 95% CI p
illip class 1 3.09 1.50–6.30 0.002
ge 60 yrs 2.96 1.12–7.83 0.03
edical history of CABG 3.46 1.34–8.93 0.01
reatinine 1.1 3.23 1.22–8.57 0.02
PLA2 activity, third tertile 3.08 1.37–6.91 0.006
nivariate predictors with a p  0.05 (Table 3) were included in a stepwise
ultivariable Cox regression model. The selection method was a forward selection
ith a significance level of 0.05 for entering an explanatory variable into the model.
he final model only includes significant variables with a p 0.05 with the Wald test.
CI  confidence interval; other abbreviations as in Tables 1 and 3.
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.28 hazard ratio associated with high CRP levels.
On the basis of experimental data by our group and
thers showing a potent proatherogenic role for endogenous
L-18 (24–26), plasma IL-18 level has been measured in
atients with a history of CAD and in healthy middle-aged
en and was found to be of predictive value for the
ccurrence of coronary events (27,28). In the present study,
e found no association between IL-18 level and adverse
utcomes in patients with ACS. These results, taken to-
ether, suggest that the prognostic value of IL-18 varies
ccording to disease activity at the time of sampling. This
ould be related to multiple factors, including untested
onfounding variables, a differential role of IL-18 in differ-
nt clinical settings, or to differences in the production of
L-18 binding protein, the endogenous inhibitor of IL-18.
hese considerations should be taken into account in future
tudies when evaluating the prognostic implications of
L-18 in patients with ACS.
The most important and novel finding in the present
tudy is the demonstration that a single determination of
PLA2 activity, obtained during the two days after the onset
f ischemic symptoms, provides powerful prognostic infor-
ation in patients with ACS. The association between
PLA2 activity and the risk of subsequent death or MI was
ndependent of the other known predictors of major adverse
utcomes in patients with ACS, including the presence or
bsence of a history of MI and the presence or absence of
linical signs of heart failure at admission (9). Interestingly,
his finding of a strong predictive value of sPLA2 was
btained despite the heterogeneity of the sample under
tudy regarding clinical presentation, pathophysiology, the
isk associated with each type of ACS, and the high rate of
n-hospital revascularization, consistent with the current
veryday practice. This suggests that activation of sPLA2
ight be a critical and common mechanism among patients
t risk for death or MI after an acute coronary syndrome.
ecretory PLA2 activity was higher in patients recruited in
cotland than in patients recruited in France (Table 2). This
ight be related, at least in part, to the higher age of
atients recruited in Scotland (p  0.0001 in comparison
ith France) and the higher percentage of Scottish patients
ith a Killip class1 at admission (34.52% vs. only 12.02%
n the French sample of patients) (p  0.0001).
A previous small study has demonstrated that in patients
ith UA, a higher plasma level of sPLA2 was associated
ith a higher probability of developing clinical coronary
vents, mainly coronary revascularizations and readmissions,
uring a follow-up period of two years (6). This previous
tudy focused on a limited number of homogeneous patients
nd included only 52 patients with UA who had no increase
n biochemical markers of necrosis. In addition, no direct
easurement of sPLA2 activity was performed. Our study
xtends these previous findings to the whole spectrum of
CS and shows that sPLA2 activity is a strong andndependent predictor of death or MI. iUnlike traditional cardiac biomarkers used to predict
dverse outcome in patients with ACS, sPLA2 activity has
een shown to act at multiple critical pathways involved in
therogenesis (3), from lipid oxidation (29) to modulation
f vascular and inflammatory cell activation and apoptosis
30–32). Interestingly, sPLA2 is already expressed in the
ormal arterial wall (2,33), and its expression is readily
p-regulated by inflammatory stimuli (30,31,34–36), sug-
esting a potential role for sPLA2 beginning in the early
hases of the vessel response to injury. Secretory PLA2
timulates the oxidation of native LDL (29) and is involved
n the release of polyunsaturated fatty acids, leading to the
roduction of biologically active phospholipids (37). These
xidation products play important roles in platelet, mono-
yte, and endothelial activation, processes known to be
ritical steps in atherogenesis (38). Lysophospholipids, in-
luding lysophosphatidylcholine and lysophosphatidic acid,
eleased from the cell membrane of platelets and other cells
n the form of microvesicles following sPLA2 activation
39), can influence cellular functions (40,41) and lead to the
eneration of platelet-activating factor, a potent cell activa-
or and a potentially proatherogenic factor. Of major im-
ortance, sPLA2 is virtually inactive on phospholipids from
ntact cells, and several studies suggest that only those
embranes where the transverse distribution of phospho-
ipids has been disturbed offer a convenient surface able to
nteract with the enzyme (42). We have previously shown
ncreased levels of intraplaque and circulating shed-
embrane microparticles presenting an altered phospho-
ipid distribution, with phosphatidylserine exposure at the
uter leaflet of the membrane, in patients with ACS
43,44). We believe that these microparticles might consti-
ute an important substrate for sPLA2, both at the site of
laque complication and in the circulating blood. Taken
ogether, these data suggest that sPLA2 activity, in the
rterial wall and the circulating blood, might play a critical
ole in inflammatory pathways leading to ACS, and might
xplain, at least in part, the more than three-fold increase in
he risk of death or new or recurrent MI in patients with
CS.
There are a number of study limitations that should be
cknowledged. The relationship between sPLA2 activity
nd inflammatory mediators has not been assessed in detail.
articularly, measurement of serum amyloid A levels, an
cute phase protein whose transport is partially regulated by
DL cholesterol and whose serum levels are known to be
nhanced in ACS (45), could have provided additional
nsights into the interaction between lipids, inflammatory
ediators, and sPLA2. Another limitation is the relatively
mall number of patients in our study. Indeed, the study was
lanned to detect an adjusted relative risk of three. Moder-
te effect sizes could not reach statistical significance.
In conclusion, the level of sPLA2 activity, measured at
he time of enrolment in patients with ACS, is a strong
redictor of death and MI. This study should be confirmed
n other populations of patients with ACS before level of
s
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